Skip to main content
. 2021 Oct 21;12:6120. doi: 10.1038/s41467-021-25731-z

Fig. 1. HDL-C, CETP inhibitor, and CHD: genome-wide biomarker vs. drug target MR.

Fig. 1

Forest plot of the HDL-C biomarker MR estimate (Holmes et al., 2015), drug target MR estimate of CETP level and function using HDL-C as a proxy (Schmidt et al., 2020), and odds ratio of anacetrapib clinical trial (HPS3/TIMI55–REVEAL Collaborative Group, 2017). OR odds ratio, CI confidence interval, SD standard deviation.